Active CD19 protein-coupled magnetic Beads

• Cat.No.: CD19-7098M

Specification

• Species: Human
• Appearance: Powder mixture
• Particle size: 2 μm
• Source: HEK293
• Protein length: Pro 20 - Lys 291
• Bio-activity: Immobilized 54 μg CD19 protein to 1 mg Beads, can bind the Anti-CD19 Antibody with an EC50 of 0.8888 μg/mL.
• Coupled amount of protein: ≈1151 pmol (38.8 μg) CD19/mg Beads
• Capacity: >150 pmol (25 μg) antibody/mg beads
• Formulation: PBS, pH7.4, with 10% Trehalose
• Reconstitution: 2 mL sterile deionized water (1 mg beads/mL)
• Background: The biotinylated CD19 protein was conjugated to streptavidin magnetic beads. This pre-coupled magnetic bead product can capture the anti-CD19 antibody from various assay systems. The beads are in uniform size, narrow size distribution with large surface area and unique surface coating, which can help you get the best performance and highly reproducible results. This CD19 coupled magnetic beads will bring great convenience with minimum non-specific binding and developed protocols. This ready-to-use product could greatly save your time and hassle.
• Application: This product is intended for immunocapture, biopanning and flow cytometry. This product is produced non-sterile.
• Storage: Upon receipt, please store the Beads at -20°C for 1 year in lyophilized state.

Reviews

01/02/2023

The manufacturer of CD19 protein has consistently provided outstanding technical support that has surpassed my expectations.

08/18/2022

This protein demonstrates remarkable purity, stability, and specificity, ensuring utmost accuracy and reproducibility in my research endeavors.

06/29/2016

Their dedication to customer satisfaction has been instrumental in overcoming obstacles and achieving successful results in my experiments.

Q&As

How does CAR-T cell therapy work to combat CD19-expressing cancers?

CAR-T cells are engineered to express a receptor that recognizes CD19 on the surface of cancerous B cells. When they encounter these cells, they destroy them.

Are there any diseases associated with CD19 dysfunction?

CD19 deficiencies can lead to primary immunodeficiencies, making individuals more susceptible to infections.

What are the potential side effects of CAR-T cell therapy targeting CD19?

Side effects may include cytokine release syndrome (CRS), neurologic toxicity, and long-term B-cell aplasia.

What are some CD19-expressing malignancies that CAR-T cell therapy can target?

CAR-T cell therapy is used to treat B-cell malignancies such as acute lymphoblastic leukemia (ALL) and certain types of non-Hodgkin lymphoma.

How effective is CAR-T cell therapy in treating CD19-expressing cancers?

CAR-T cell therapy has shown remarkable effectiveness in inducing remissions in patients with CD19-positive malignancies, particularly in those who have relapsed or failed conventional treatments.